KORRO BIO INC. - COMM

Korro to Participate in Upcoming Investor Conferences

21 نوفمبر 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

21 نوفمبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Korro to Present at the Jefferies London Healthcare Conference

14 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 نوفمبر 2024 15:05:02 بحسب Nasdaq GlobeNewswire

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

04 نوفمبر 2024 06:25:00 بحسب Nasdaq GlobeNewswire

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

30 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

16 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Korro to Participate in Upcoming Investor Conferences

10 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

28 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Korro to Participate in Upcoming September Investor and Scientific Conferences

27 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

13 أغسطس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes

01 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Korro to Participate in Upcoming June Investor and Scientific Conferences

30 مايو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

20 مايو 2024 13:30:00 بحسب Nasdaq GlobeNewswire

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

14 مايو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Korro Announces $70 Million Private Placement

18 أبريل 2024 07:30:59 بحسب Nasdaq GlobeNewswire

Korro to Participate in Upcoming Investor Conferences

01 أبريل 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

26 مارس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Korro to Present at the TD Cowen 44th Annual Health Care Conference

27 فبراير 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

18 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire